Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease

Suzuki, Masahiko; Yoshioka, Masayuki; Hashimoto, Masaya; Murakami, Maiko; Noya, Miki; Takahashi, Daisuke; Urashima, Mitsuyoshi

doi:10.3945/ajcn.112.051664

Cited by 189 publications

(148 citation statements)

References 29 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…Deficiency of Vitamin D or loss of VDR is usually associated with risk of several neurodevelopmental disorders to loss of antiproliferative functions, thus the absence of VDR or VitD 3 deprives the neurons of needed signals. The studies of Suzuki et al [39] also corroborated this finding that Vitamin D deficiency is a predisposing factor to increased progression of PD. The findings of this study suggest that the progression of such disease conditions is related to process formation and synaptic denervation.…”

Section: Discussionsupporting

confidence: 75%

VDR Potentiation and NMDA R Inhibition Facilitates Axo-Dendritic Process Formation in Melanocyte Model for Pigmented Cells in Parkinsonism

Michael

Ajonijebu²,

Chris³

et al. 2013

Cell Development Biol

View full text Add to dashboard Cite

Background: A major cellular change in dopaminergic neurons leading to Parkinsonism is the alteration of microtubule proteins that causes accumulation of tau protein, α-syn and β-amyloid plaque in the cells. In this study we investigate the role of Vitamin D 3 in relieving the symptoms of Parkinsonism as it is capable of stimulating polymerization of microtubules. The Microtubules (MT) system in the fish scale melanocytes has been modeled for the dopaminergic neurons of the Substantia Nigra (SN). These cells are capable of forming cellular processes similar to what is seen in the dopaminergic neurons; in this study, we investigate the protective effect of Vitamin D 3 Receptor Agonist (VDRA) and N-Methyl-D-Aspartate Receptor (NMDA R) inhibition in process formation, synaptic denervation and melanin loss in fish scale melanocytes modeled as pigmented adrenergic cells.

show abstract

Section: Discussionsupporting

confidence: 75%

VDR Potentiation and NMDA R Inhibition Facilitates Axo-Dendritic Process Formation in Melanocyte Model for Pigmented Cells in Parkinsonism

Michael

Ajonijebu²,

Chris³

et al. 2013

Cell Development Biol

View full text Add to dashboard Cite

show abstract

“…In fact, there is an overexpression of PARP1 in the substantia nigra of PD patients [281]; increased levels of vitamin D down regulate PARP-1 expression, probably mediated by a diminishment of microglial activation [282]. All these aspects considered, clinical trials on vitamin D supplementation in Parkinson's disease have been carried out [283]. Although some data demonstrated that low levels of vitamin D may influence the speed of the disease [283], the supplementation of vitamin D did not modify the disease outcomes.…”

Section: Vitamin D Deficiency and Neurodegenerative Diseasesmentioning

confidence: 99%

“…All these aspects considered, clinical trials on vitamin D supplementation in Parkinson's disease have been carried out [283]. Although some data demonstrated that low levels of vitamin D may influence the speed of the disease [283], the supplementation of vitamin D did not modify the disease outcomes. That conclusion probably lies on clinical time of supplementation, far from the initial ones of labs models.…”

Section: Vitamin D Deficiency and Neurodegenerative Diseasesmentioning

confidence: 99%

Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact

Moretti

Morelli

Caruso

2018

Preprint

View full text Add to dashboard Cite

It is widely known that vitamin D receptors have been found in neurons and glial cells and their highest expression is in the hippocampus, hypothalamus, thalamus and subcortical grey nuclei, and substantia nigra. The vitamin D helps the regulation of neurotrophin, neural differentiation and maturation, through the control operation of growing factors synthesis (ie NGF and GDNF), the trafficking of the septo-hyppocampal pathway, and the control of the synthesis process of different neuromodulators (such as Ach, DA, and GABA).Based on these assumptions, we have written this review in order to summarize the potential role of vitamin D in neurological pathologies. The work could be titanic, and might result very fuzzy and even incoherent, if we would not have conjectured to taper our first intentions and devoted our interests towards three mainstreams: demyelinating pathologies, vascular syndromes and neurodegeneration.Due to the lack of effective therapeutic options, a part from the disease modifying strategies, the role of different risk factors should be investigated in neurology, as far as their correction may lead to the improvement of the cerebral conditions.We have explored the relationships between the gene-environmental influence and long term vitamin D deficiency, as a risk factor for the development of different types of neurological disorders, along with the role and the rationale of therapeutic trials with vitamin D implementation. Peer-reviewed version available at Int. J. Mol. Sci. 2018, 19, 2245 doi:10.3390/ijms19082245 3 SEARCH STRATEGY AND SELECTION CRITERIAWe searched MEDLINE using the search terms: "vitamin D central nervous system" , both "vitamin D" and "central nervous system"; "vitamin D immune system/response", both "vitamin D" and "immune system" or "immune response"; "vitamin D multiple sclerosis risk", both "vitamin D" and "multiple sclerosis risk"; "vitamin D multiple sclerosis relapse", both "vitamin D" and "multiple sclerosis relapse"; "vitamin D multiple sclerosis magnetic resonance imaging", both "vitamin D" and "multiple sclerosis magnetic resonance imaging"; "vitamin D multiple sclerosis disability", both "vitamin D" and "multiple sclerosis disability"; "vitamin D supplementation/therapy/treatment multiple sclerosis", both "vitamin D supplementation" or "vitamin D therapy" or "vitamin D treatment" and "multiple sclerosis"; "vascular dementia", both as -vascular-and -dementia-, "subcortical vascular dementia", both assubcortical-and -dementia-, "Alzheimer's disease", "pathogenesis neurodegeneration" "amyloid", "cholinergic afferents", "arteriolosclerosis", "cerebral flow regulation", "stroke". Publications were selected mostly form the past 20years, but did not exclude frequently referenced and highly regarded older publications. . Congress abstracts and isolated case reports were not considered. We searched the reference lists of articles identified by this search strategy and selected those we judged relevant. Review articles and book chapters are cited to provide with ...

show abstract

“…Supplementation with vitamin D is shown to be beneficial in slowing disease progression in animal and cell culture models of PD, [23]. A recent study showed that vitamin D3 supplements stabilized motor symptoms among PD patients [24]. However, it is not clear if a reduction in vitamin D due to nutritional deficiency causes an increase in PD and/or if UV radiation or exposure to sunlight plays a role.…”

Section: Neuroprotective Nutrients Vitaminsmentioning

confidence: 99%

Current Understanding on the Beneficial Role of Nutrition in Parkinson’s Disease –An Overview

Muralidhara¹,

Sv²,

SC³

2017

J Aging Sci

View full text Add to dashboard Cite

Various nutritional components belonging to different classes of natural dietary origin display modulatory (protective) properties against age-related neurodegenerative disorders (NDD) such as Parkinson's disease (PD) and Alzheimer's disease. These compounds termed as nutraceuticals which have been shown to act at various biochemical and metabolic levels and exhibit different degree of neuroprotective properties. Present review aims to summarize the current status on the modulatory impact of some of the major nutritional compounds on the pathophysiology of PD, the second most common NDD in humans. Primarily, we have examined the data demonstrated in animal models and postulated through epidemiological studies on the compounds/molecules/life style factors which reduce the risk associated with PD and probable mechanism/s through which they elicit neuroprotection. Further we also included some of the conflicting information about the compounds which may enhance the risk associated with PD. Additionally, emphasis is also given about the new approaches to understand the impact of nutrition on the epigenome in relation to the development of NDD with a short note on emerging ideas relating to nutritional genomics.

show abstract

Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in Parkinson disease

Abstract: Vitamin D3 supplementation may stabilize PD for a short period in patients with FokI TT or CT genotypes without triggering hypercalcemia, although this effect may be nonspecific for PD. This trial was registered at UMIN Clinical Trials Registry as UMIN000001841.

Cited by 189 publications

References 29 publications

VDR Potentiation and NMDA R Inhibition Facilitates Axo-Dendritic Process Formation in Melanocyte Model for Pigmented Cells in Parkinsonism

VDR Potentiation and NMDA R Inhibition Facilitates Axo-Dendritic Process Formation in Melanocyte Model for Pigmented Cells in Parkinsonism

Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact

Current Understanding on the Beneficial Role of Nutrition in Parkinson’s Disease –An Overview

Contact Info

Product

Resources

About